Identification

Name
Omeprazole
Accession Number
DB00338  (APRD00446)
Type
Small Molecule
Groups
Approved, Investigational, Vet Approved
Description

A highly effective inhibitor of gastric acid secretion used in the therapy of stomach ulcers and Zollinger-Ellison syndrome. Omeprazole belongs to a class of antisecretory compounds, the substituted benzimidazoles, that suppress gastric acid secretion by specific inhibition of the H+/K+ ATPase enzyme system at the secretory surface of the gastric parietal cell.

Structure
Thumb
Synonyms
  • OMEP
  • Omeprazol
  • Omeprazolum
Product Ingredients
IngredientUNIICASInChI Key
Omeprazole magnesium426QFE7XLK95382-33-5KWORUUGOSLYAGD-UHFFFAOYSA-N
Omeprazole sodiumKV03YZ6QLW95510-70-6RYXPMWYHEBGTRV-UHFFFAOYSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Auro-omeprazoleCapsule, delayed release20 mgOralAuro Pharma Inc2014-03-26Not applicableCanada
Auro-omeprazoleCapsule, delayed release10 mgOralAuro Pharma Inc2014-03-26Not applicableCanada
Ava-omeprazoleCapsule, delayed release20 mgOralAvanstra Inc2011-11-282014-08-21Canada
Bio-omeprazoleTablet, delayed release20 mgOralBiomed Pharma2016-09-07Not applicableCanada
Dom-omeprazole DrTablet, delayed release20 mgOralDominion Pharmacal2013-01-23Not applicableCanada
Dom-omeprazole DrTablet, delayed release10 mgOralDominion PharmacalNot applicableNot applicableCanada
Jamp-omeprazole DrTablet, delayed release20 mgOralJamp Pharma Corporation2014-02-11Not applicableCanada
Leader OmeprazoleTablet, delayed release20 mg/1OralRemedy Repack2013-06-042017-01-04Us
Losec 10 mgTablet, delayed release10 mgOralAstra Zeneca1997-04-28Not applicableCanada
Losec 20 mgTablet, delayed release20 mgOralAstra Zeneca1996-12-31Not applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-omeprazoleCapsule, delayed release20 mgOralApotex Corporation2004-01-28Not applicableCanada
Apo-omeprazoleCapsule, delayed release40 mgOralApotex CorporationNot applicableNot applicableCanada
OmeprazoleCapsule, delayed release20 mg/1OralRemedy Repack2013-04-222016-11-04Us
OmeprazoleCapsule, delayed release40 mg/1OralGlenmark Pharmaceuticals Inc.,Usa2014-10-31Not applicableUs
OmeprazoleCapsule, delayed release20 mg/1OralBlenheim Pharmacal, Inc.2015-03-10Not applicableUs
OmeprazoleCapsule, delayed release40 mg/1OralLake Erie Medical Dba Quality Care Produts Llc2009-01-21Not applicableUs
OmeprazoleCapsule, delayed release20 mg/1OralRemedy Repack2013-03-062016-12-01Us
OmeprazoleCapsule, delayed release20 mg/1OralAurobindo Pharma2015-08-19Not applicableUs
OmeprazoleCapsule, delayed release20 mg/1OralProficient Rx LP2014-10-31Not applicableUs
OmeprazoleCapsule, delayed release20 mg/1Oralbryant ranch prepack2009-01-21Not applicableUs
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Acid ReducerCapsule, delayed release20 mg/1OralCardinal Health2017-03-07Not applicableUs
Ahi-omeprazoleTablet, delayed release20 mgOralAccord Healthcare LimitedNot applicableNot applicableCanada
Basic Care OmeprazoleTablet, delayed release20 mg/1OralL. Perrigo Company2017-08-08Not applicableUs
Basic Care OmeprazoleCapsule, delayed release20 mg/1OralL. Perrigo Company2017-08-08Not applicableUs
Being Well OmeprazoleTablet, delayed release20 mg/1OralSave A Lot Food Stores, Ltd.2008-03-20Not applicableUs
Berkley and Jensen OmeprazoleTablet, delayed release20 mg/1OralBJWC2008-02-28Not applicableUs
Care One OmeprazoleTablet, delayed release20 mg/1OralAmerican Sales Company2008-02-29Not applicableUs
Core Values OmeprazoleTablet, delayed release20 mg/1OralHarmon Stores2016-11-22Not applicableUs
Dg Health OmeprazoleTablet, delayed release20 mg/1OralDolgencorp2010-02-14Not applicableUs
Equaline OmeprazoleTablet, delayed release20 mg/1OralSupervalu2008-02-22Not applicableUs
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
OmeprazoleCapsule, delayed release40 mg/1OralPreferreed Pharmaceuticals Inc.2017-10-27Not applicableUs
OmeprazoleCapsule, delayed release40 mg/1OralNu Care Pharmaceuticals,inc.2009-01-23Not applicableUs
OmeprazoleCapsule, delayed release40 mg/1OralNu Care Pharmaceuticals,inc.2009-01-23Not applicableUs
OmeprazoleCapsule20 mg/1OralReliable 1 Laboratories2017-08-16Not applicableUs
International/Other Brands
Antra / Audazol / Belmazol / Ceprandal / Danlox / Desec / Elgam / Emeproton / Gasec / Gastrimut / Gastroloc / Indurgan / Inhibitron / Logastric / Losec / Mepral / Mopral / Olexin / Omapren / Omepral / Omeprazon / Omeprol / Omezol / Omisec / Omizac / Ortanol / Parizac / Prazidec / Prazolit / Procelac / Ramezol / Regulacid / Sanamidol / Ulceral / Ulcesep / Ultop / Zepral
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Good Sense Omeprazole and Sodium BicarbonateOmeprazole (20 mg/1) + Sodium bicarbonate (1100 mg/1)Capsule, gelatin coatedOralL. Perrigo Company2017-06-19Not applicableUs
Not ApplicableOmeprazole (40 mg/1) + Sodium bicarbonate (1100 mg/1)CapsuleOralSterling Knight Pharmaceuticals, Llc2017-07-13Not applicableUs
Omeclamox-PakOmeprazole + Amoxicillin + ClarithromycinKitPernix Therapeutics2012-04-27Not applicableUs
Omeclamox-PakOmeprazole + Amoxicillin + ClarithromycinKitCumberland Pharmaceuticals2012-04-27Not applicableUs
Omeprazole and sodium bicarbonateOmeprazole (20 mg/1) + Sodium bicarbonate (1100 mg/1)Capsule, gelatin coatedOralH.E.B.2017-08-25Not applicableUs
Omeprazole and Sodium BicarbonateOmeprazole (20 mg/1) + Sodium bicarbonate (1100 mg/1)CapsuleOralNorth Star Rx Llc2016-07-15Not applicableUs
Omeprazole and Sodium BicarbonateOmeprazole (20 mg/1) + Sodium bicarbonate (1100 mg/1)Capsule, gelatin coatedOralCVS Health2016-07-15Not applicableUs
Omeprazole and Sodium BicarbonateOmeprazole (40 mg/1) + Sodium bicarbonate (1680 mg/1)Powder, for suspensionOralOceanside Pharmaceuticals2004-06-15Not applicableUs
Omeprazole and Sodium BicarbonateOmeprazole (40 mg/1) + Sodium bicarbonate (1100 mg/1)CapsuleOralAjanta Pharma Limited2016-07-15Not applicableUs
Omeprazole and Sodium BicarbonateOmeprazole (20 mg/1) + Sodium bicarbonate (1100 mg/1)CapsuleOralAurolife Pharma, LLC2014-09-30Not applicableUs
Categories
UNII
KG60484QX9
CAS number
73590-58-6
Weight
Average: 345.416
Monoisotopic: 345.114712179
Chemical Formula
C17H19N3O3S
InChI Key
SUBDBMMJDZJVOS-UHFFFAOYSA-N
InChI
InChI=1S/C17H19N3O3S/c1-10-8-18-15(11(2)16(10)23-4)9-24(21)17-19-13-6-5-12(22-3)7-14(13)20-17/h5-8H,9H2,1-4H3,(H,19,20)
IUPAC Name
6-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methanesulfinyl]-1H-1,3-benzodiazole
SMILES
COC1=CC2=C(C=C1)N=C(N2)S(=O)CC1=NC=C(C)C(OC)=C1C

Pharmacology

Indication

Omeprazole is indicated for the treatment of duodenal ulcers, benign gastric ulcers, gastroesophageal reflux disease (GERD), heartburn and other symptoms associated with GERD, erosive esophagitis, and long-term treatment of pathological hypersecretory conditions like Zollinger-Ellison syndrome, multiple endocrine adenomas, and systemic mastocytosis.

Structured Indications
Pharmacodynamics

After oral administration, the onset of the anti-secretory effect of omeprazole occurs within one hour and maximum effect occurring within two hours. At 24 hours, inhibition of secretion is approximately 50% of maximum and duration of inhibition lasts up to 72 hours. Although omeprazole has a very short plasma half-life, the anti-secretory effect lasts for a long time due to prolonged binding to parietal H+/K+ ATPase enzyme. When the drug has been discontinued, secretory activity will return to baseline over 3-5 days. The inhibitory effect of omeprazole on acid secretion increases with repeated once-daily dosing, reaching a plateau after four days. In studies involving more than 200 patients, serum gastrin levels increased during the first 1 to 2 weeks of once-daily administration of therapeutic doses of omeprazole in parallel with inhibition of acid secretion. Systemic effects of omeprazole in the CNS, cardiovascular and respiratory systems have not been found to date.

Mechanism of action

Omeprazole is a proton pump inhibitor that suppresses gastric acid secretion by specific inhibition of the H+/K+-ATPase in the gastric parietal cell. By acting specifically on the proton pump, omeprazole blocks the final step in acid production, thus reducing gastric acidity.

TargetActionsOrganism
APotassium-transporting ATPase alpha chain 1
inhibitor
Human
UAryl hydrocarbon receptor
agonist
Human
Absorption

The delayed-release capsule are enteric-coated (as omeprazole is acid-labile) so the absorption of omprazole begins once the granules leave the stomach. Absorption is rapid. Peak plasma levels occur within 0.5 - 3.5 hours. The absolute bioavailability (compared with intravenous administration) of the delayed-release capsule is 30-40% at doses of 20 - 40 mg, due to presystemic metabolism. This value increases slightly when given repeatedly. Based on a relative bioavailability study, the AUC and Cmax of PRILOSEC (omeprazole magnesium) for Delayed-Release Oral Suspension were 87% and 88% of those for PRILOSEC Delayed-Release Capsules, respectively. Interestingly, when the 40 mg delayed release capsule is given with or without applesauce, it is bioequivalent. However, when the 20 mg delayed release capsule is given with the same conditions, it is not bioequivalent. When the same capsule is given to the elderly, bioavailability increases. Omeprazole was 76% bioavailable.

Volume of distribution
Not Available
Protein binding

95% bound to human plasma protein.

Metabolism

Hepatic. Omeprazole is extensively metabolized by the cytochrome P450 (CYP) enzyme system. The two primary CYP isozymes involved are CYP2C19 and CYP3A4. Metabolism is stereoselective in which the S-isomer is converted to 5'O-desmethylomeprazole via CYP2C19. CYP3A4 converts the S-isomer to 3-hydroxyomeprazole. The R-isomer is converted to 5-hydroxyomeprazole by CYP2C19. CYP3A4 converts the R-isomer to any four different metabolites: 5-hydroxyomeprazole (5-OH OME), omeprazole sulfone (OME sulfone), 5'-O-desmethylomeprazole (5'-desmethyl OME), and 3-hydroxyomeprazole (3-OH OME).

Route of elimination

Urinary excretion is a primary route of excretion of omeprazole metabolites. Little, if any unchanged drug was excreted in the urine. The majority of the dose (about 77%) was eliminated in urine as at least six metabolites. Two were identified as hydroxyomeprazole and the corresponding carboxylic acid. The remainder of the dose was recovered in the feces.

Half life

0.5-1 hour (healthy subjects, delayed-release capsule); 3 hours (hepatic impairment)

Clearance
  • 500 - 600 mL/min [Total body clearance, healthy subjects, delayed-release capsule]
  • 250 mL/min [Plasma clearance, Geriatric]
  • 70 mL/min [Plasma clearance, Hepatic Impairment]
Toxicity

Symptoms of overdose include confusion, drowsiness, blurred vision, tachycardia, nausea, diaphoresis, flushing, headache, and dry mouth.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Omeprazole Action PathwayDrug action
Omeprazole Metabolism PathwayDrug metabolism
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeAllele nameGenotype(s)Defining Change(s)Type(s)DescriptionDetails
Cytochrome P450 2C19CYP2C19*2(A;A)A Allele, homozygoteEffect Directly StudiedPatients with this genotype have reduced metabolism of omeprazole.Details
Cytochrome P450 2C19CYP2C19*3(A;A)A Allele, homozygoteEffect Directly StudiedPatients with this genotype have reduced metabolism of omeprazole.Details
Cytochrome P450 2C19CYP2C19*2ANot Available681G>AEffect InferredPoor metabolizer, lower dose requirement, improved drug efficacyDetails
Cytochrome P450 2C19CYP2C19*2BNot Available681G>AEffect InferredPoor metabolizer, lower dose requirement, improved drug efficacyDetails
Cytochrome P450 2C19CYP2C19*4Not Available1A>GEffect InferredPoor metabolizer, lower dose requirement, improved drug efficacyDetails
Cytochrome P450 2C19CYP2C19*5Not Available1297C>TEffect InferredPoor metabolizer, lower dose requirement, improved drug efficacyDetails
Cytochrome P450 2C19CYP2C19*6Not Available395G>AEffect InferredPoor metabolizer, lower dose requirement, improved drug efficacyDetails
Cytochrome P450 2C19CYP2C19*7Not Available19294T>AEffect InferredPoor metabolizer, lower dose requirement, improved drug efficacyDetails
Cytochrome P450 2C19CYP2C19*22Not Available557G>C / 991A>GEffect InferredPoor metabolizer, lower dose requirement, improved drug efficacyDetails
Cytochrome P450 2C19CYP2C19*24Not Available99C>T / 991A>G  … show all Effect InferredPoor metabolizer, lower dose requirement, improved drug efficacyDetails
Cytochrome P450 2C19CYP2C19*35Not Available12662A>GEffect InferredPoor metabolizer, lower dose requirement, improved drug efficacyDetails

Interactions

Drug Interactions
DrugInteractionDrug group
AbirateroneThe serum concentration of Omeprazole can be increased when it is combined with Abiraterone.Approved
AceclofenacThe metabolism of Aceclofenac can be decreased when combined with Omeprazole.Approved, Investigational
AcenocoumarolThe serum concentration of Acenocoumarol can be increased when it is combined with Omeprazole.Approved
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Omeprazole.Approved
Acetylsalicylic acidThe metabolism of Acetylsalicylic acid can be decreased when combined with Omeprazole.Approved, Vet Approved
AdinazolamThe metabolism of Adinazolam can be decreased when combined with Omeprazole.Approved
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Omeprazole.Approved
Alendronic acidThe therapeutic efficacy of Alendronic acid can be decreased when used in combination with Omeprazole.Approved
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Omeprazole.Approved, Investigational
AlosetronThe metabolism of Alosetron can be decreased when combined with Omeprazole.Approved, Withdrawn
AlprazolamThe metabolism of Alprazolam can be decreased when combined with Omeprazole.Approved, Illicit, Investigational
AmbrisentanThe metabolism of Ambrisentan can be decreased when combined with Omeprazole.Approved, Investigational
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Omeprazole.Approved, Withdrawn
AmiodaroneThe metabolism of Omeprazole can be decreased when combined with Amiodarone.Approved, Investigational
AmitriptylineThe metabolism of Amitriptyline can be decreased when combined with Omeprazole.Approved
AmoxicillinThe metabolism of Amoxicillin can be decreased when combined with Omeprazole.Approved, Vet Approved
AmphetamineOmeprazole can cause an increase in the absorption of Amphetamine resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved, Illicit
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Omeprazole.Approved
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Omeprazole.Approved
ApixabanThe metabolism of Apixaban can be decreased when combined with Omeprazole.Approved
AprepitantThe serum concentration of Omeprazole can be increased when it is combined with Aprepitant.Approved, Investigational
Arachidonic AcidThe metabolism of Arachidonic Acid can be decreased when combined with Omeprazole.Experimental
ArformoterolThe metabolism of Arformoterol can be decreased when combined with Omeprazole.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Omeprazole.Approved, Investigational
ArmodafinilThe metabolism of Omeprazole can be decreased when combined with Armodafinil.Approved, Investigational
ArtemetherThe metabolism of Artemether can be decreased when combined with Omeprazole.Approved
AtazanavirOmeprazole can cause a decrease in the absorption of Atazanavir resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
AtomoxetineThe metabolism of Omeprazole can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Omeprazole is combined with Atorvastatin.Approved
AxitinibThe metabolism of Axitinib can be decreased when combined with Omeprazole.Approved, Investigational
AzelastineThe metabolism of Azelastine can be decreased when combined with Omeprazole.Approved
AzithromycinThe metabolism of Omeprazole can be decreased when combined with Azithromycin.Approved
BenzatropineThe metabolism of Benzatropine can be decreased when combined with Omeprazole.Approved
BexaroteneThe metabolism of Bexarotene can be decreased when combined with Omeprazole.Approved, Investigational
BoceprevirThe metabolism of Omeprazole can be decreased when combined with Boceprevir.Approved, Withdrawn
BortezomibThe metabolism of Omeprazole can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Bosentan can be increased when it is combined with Omeprazole.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be decreased when it is combined with Omeprazole.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Omeprazole.Approved
BrivaracetamThe metabolism of Brivaracetam can be decreased when combined with Omeprazole.Approved, Investigational
BromazepamThe metabolism of Bromazepam can be decreased when combined with Omeprazole.Approved, Illicit
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Omeprazole.Approved, Investigational
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Omeprazole.Approved
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Omeprazole.Approved, Investigational
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Omeprazole.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Bupropion can be decreased when combined with Omeprazole.Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Omeprazole.Approved
CabozantinibThe metabolism of Cabozantinib can be decreased when combined with Omeprazole.Approved
CaffeineThe metabolism of Omeprazole can be decreased when combined with Caffeine.Approved
CandesartanThe metabolism of Candesartan can be decreased when combined with Omeprazole.Experimental
Candesartan cilexetilThe metabolism of Candesartan cilexetil can be decreased when combined with Omeprazole.Approved
CapecitabineThe metabolism of Omeprazole can be decreased when combined with Capecitabine.Approved, Investigational
CarbamazepineThe metabolism of Omeprazole can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Omeprazole.Approved
CarisoprodolThe metabolism of Carisoprodol can be decreased when combined with Omeprazole.Approved
CarvedilolThe serum concentration of Carvedilol can be increased when it is combined with Omeprazole.Approved, Investigational
CefditorenThe serum concentration of Cefditoren can be decreased when it is combined with Omeprazole.Approved
CelecoxibThe metabolism of Celecoxib can be decreased when combined with Omeprazole.Approved, Investigational
CeritinibThe serum concentration of Omeprazole can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Omeprazole.Withdrawn
ChloramphenicolThe metabolism of Omeprazole can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChlorpropamideThe metabolism of Chlorpropamide can be decreased when combined with Omeprazole.Approved
CholecalciferolThe metabolism of Omeprazole can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Omeprazole.Approved
CimetidineThe metabolism of Omeprazole can be decreased when combined with Cimetidine.Approved
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Omeprazole.Approved, Investigational
CisaprideThe metabolism of Cisapride can be decreased when combined with Omeprazole.Approved, Investigational, Withdrawn
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Omeprazole.Approved
ClarithromycinThe metabolism of Omeprazole can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Omeprazole can be decreased when combined with Clemastine.Approved
ClobazamThe metabolism of Clobazam can be decreased when combined with Omeprazole.Approved, Illicit
Clodronic AcidThe therapeutic efficacy of Clodronic Acid can be decreased when used in combination with Omeprazole.Approved, Investigational, Vet Approved
clomethiazoleThe metabolism of clomethiazole can be decreased when combined with Omeprazole.Investigational
ClomipramineThe metabolism of Clomipramine can be decreased when combined with Omeprazole.Approved, Vet Approved
ClopidogrelOmeprazole may decrease the antiplatelet activities of Clopidogrel.Approved, Nutraceutical
ClorindioneThe serum concentration of Clorindione can be increased when it is combined with Omeprazole.Experimental
ClotiazepamThe metabolism of Clotiazepam can be decreased when combined with Omeprazole.Approved, Illicit
ClotrimazoleThe metabolism of Omeprazole can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe serum concentration of Clozapine can be decreased when it is combined with Omeprazole.Approved
CobicistatThe metabolism of Omeprazole can be decreased when combined with Cobicistat.Approved
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Omeprazole.Approved
ConivaptanThe serum concentration of Omeprazole can be increased when it is combined with Conivaptan.Approved, Investigational
CrisaboroleThe metabolism of Omeprazole can be decreased when combined with Crisaborole.Approved
CrizotinibThe metabolism of Omeprazole can be decreased when combined with Crizotinib.Approved
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Omeprazole.Approved, Investigational
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
Cyproterone acetateThe serum concentration of Omeprazole can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
CysteamineThe therapeutic efficacy of Cysteamine can be decreased when used in combination with Omeprazole.Approved, Investigational
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Omeprazole.Approved
DabrafenibThe serum concentration of Omeprazole can be decreased when it is combined with Dabrafenib.Approved
DapagliflozinThe metabolism of Dapagliflozin can be decreased when combined with Omeprazole.Approved
DapsoneThe metabolism of Dapsone can be decreased when combined with Omeprazole.Approved, Investigational
DarunavirThe metabolism of Omeprazole can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Omeprazole can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Omeprazole can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Omeprazole.Approved
DesipramineThe metabolism of Desipramine can be decreased when combined with Omeprazole.Approved
DexlansoprazoleThe metabolism of Dexlansoprazole can be decreased when combined with Omeprazole.Approved
DexmethylphenidateOmeprazole can cause an increase in the absorption of Dexmethylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved
DextroamphetamineOmeprazole can cause an increase in the absorption of Dextroamphetamine resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved, Illicit
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Omeprazole.Approved
DiazepamThe metabolism of Diazepam can be decreased when combined with Omeprazole.Approved, Illicit, Vet Approved
DiclofenacThe metabolism of Diclofenac can be decreased when combined with Omeprazole.Approved, Vet Approved
DicoumarolThe serum concentration of Dicoumarol can be increased when it is combined with Omeprazole.Approved
DihydroergocornineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Omeprazole.Approved
DihydroergocristineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Omeprazole.Experimental
DihydroergocryptineThe risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Omeprazole.Experimental
DihydroergotamineThe metabolism of Omeprazole can be decreased when combined with Dihydroergotamine.Approved
DiltiazemThe metabolism of Omeprazole can be decreased when combined with Diltiazem.Approved
DiphenadioneThe serum concentration of Diphenadione can be increased when it is combined with Omeprazole.Experimental
DiphenhydramineThe metabolism of Diphenhydramine can be decreased when combined with Omeprazole.Approved
DoconexentThe metabolism of Doconexent can be decreased when combined with Omeprazole.Approved, Investigational
DolasetronThe metabolism of Dolasetron can be decreased when combined with Omeprazole.Approved
DonepezilThe metabolism of Donepezil can be decreased when combined with Omeprazole.Approved
DopamineThe metabolism of Dopamine can be decreased when combined with Omeprazole.Approved
DorzolamideThe metabolism of Dorzolamide can be decreased when combined with Omeprazole.Approved
DosulepinThe metabolism of Omeprazole can be decreased when combined with Dosulepin.Approved
DoxazosinThe metabolism of Doxazosin can be decreased when combined with Omeprazole.Approved
DoxepinThe metabolism of Doxepin can be decreased when combined with Omeprazole.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Omeprazole.Approved, Investigational
DoxycyclineThe metabolism of Omeprazole can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronabinolThe serum concentration of Dronabinol can be increased when it is combined with Omeprazole.Approved, Illicit
DronedaroneThe metabolism of Omeprazole can be decreased when combined with Dronedarone.Approved
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Omeprazole.Approved
EfavirenzThe metabolism of Omeprazole can be decreased when combined with Efavirenz.Approved, Investigational
EletriptanThe metabolism of Eletriptan can be decreased when combined with Omeprazole.Approved, Investigational
EnasidenibThe metabolism of Enasidenib can be decreased when combined with Omeprazole.Approved
EnfuvirtideThe metabolism of Enfuvirtide can be decreased when combined with Omeprazole.Approved, Investigational
EnzalutamideThe serum concentration of Omeprazole can be decreased when it is combined with Enzalutamide.Approved
EpoprostenolThe metabolism of Epoprostenol can be decreased when combined with Omeprazole.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Omeprazole.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Omeprazole.Approved
ErlotinibThe serum concentration of Erlotinib can be decreased when it is combined with Omeprazole.Approved, Investigational
ErythromycinThe metabolism of Omeprazole can be decreased when combined with Erythromycin.Approved, Vet Approved
EscitalopramThe serum concentration of Escitalopram can be increased when it is combined with Omeprazole.Approved, Investigational
Eslicarbazepine acetateThe metabolism of Omeprazole can be decreased when combined with Eslicarbazepine acetate.Approved
EsomeprazoleThe metabolism of Esomeprazole can be decreased when combined with Omeprazole.Approved, Investigational
EstradiolThe metabolism of Estradiol can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
EstroneThe metabolism of Estrone can be decreased when combined with Omeprazole.Approved
EszopicloneThe metabolism of Eszopiclone can be decreased when combined with Omeprazole.Approved
Ethyl biscoumacetateThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Omeprazole.Withdrawn
Etidronic acidThe therapeutic efficacy of Etidronic acid can be decreased when used in combination with Omeprazole.Approved
EtizolamThe metabolism of Etizolam can be decreased when combined with Omeprazole.Approved
EtodolacThe metabolism of Etodolac can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Omeprazole.Approved, Investigational
EtravirineThe metabolism of Etravirine can be decreased when combined with Omeprazole.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Omeprazole.Approved
FamotidineThe metabolism of Famotidine can be decreased when combined with Omeprazole.Approved
FelodipineThe metabolism of Omeprazole can be decreased when combined with Felodipine.Approved, Investigational
Ferric CarboxymaltoseOmeprazole can cause a decrease in the absorption of Ferric Carboxymaltose resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferric CitrateOmeprazole can cause a decrease in the absorption of Ferric Citrate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Ferric pyrophosphateOmeprazole can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Omeprazole.Approved
FloxuridineThe metabolism of Omeprazole can be decreased when combined with Floxuridine.Approved
FluconazoleThe serum concentration of Omeprazole can be increased when it is combined with Fluconazole.Approved
FluindioneThe serum concentration of Fluindione can be increased when it is combined with Omeprazole.Investigational
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Omeprazole.Approved
FlunitrazepamThe metabolism of Flunitrazepam can be decreased when combined with Omeprazole.Approved, Illicit
FluorouracilThe metabolism of Omeprazole can be decreased when combined with Fluorouracil.Approved
FluoxetineThe metabolism of Fluoxetine can be decreased when combined with Omeprazole.Approved, Vet Approved
FlurbiprofenThe metabolism of Flurbiprofen can be decreased when combined with Omeprazole.Approved, Investigational
FlutamideThe metabolism of Flutamide can be decreased when combined with Omeprazole.Approved
FluvastatinThe metabolism of Omeprazole can be decreased when combined with Fluvastatin.Approved
FluvoxamineThe metabolism of Omeprazole can be decreased when combined with Fluvoxamine.Approved, Investigational
FormoterolThe metabolism of Formoterol can be decreased when combined with Omeprazole.Approved, Investigational
FosamprenavirThe metabolism of Omeprazole can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Omeprazole can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Omeprazole.Approved
Fusidic AcidThe serum concentration of Omeprazole can be increased when it is combined with Fusidic Acid.Approved
GavestinelThe metabolism of Gavestinel can be decreased when combined with Omeprazole.Investigational
GefitinibThe serum concentration of Gefitinib can be decreased when it is combined with Omeprazole.Approved, Investigational
GemfibrozilThe metabolism of Omeprazole can be decreased when combined with Gemfibrozil.Approved
GliclazideThe metabolism of Gliclazide can be decreased when combined with Omeprazole.Approved
GlimepirideThe metabolism of Glimepiride can be decreased when combined with Omeprazole.Approved
GlipizideThe metabolism of Glipizide can be decreased when combined with Omeprazole.Approved
GlucosamineThe metabolism of Glucosamine can be decreased when combined with Omeprazole.Approved
GlyburideThe metabolism of Glyburide can be decreased when combined with Omeprazole.Approved
GuanfacineThe metabolism of Guanfacine can be decreased when combined with Omeprazole.Approved, Investigational
HaloperidolThe metabolism of Haloperidol can be decreased when combined with Omeprazole.Approved
HalothaneThe metabolism of Halothane can be decreased when combined with Omeprazole.Approved, Vet Approved
HexobarbitalThe metabolism of Hexobarbital can be decreased when combined with Omeprazole.Approved
HistamineThe metabolism of Histamine can be decreased when combined with Omeprazole.Approved, Investigational
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Omeprazole.Approved, Illicit
IbandronateThe therapeutic efficacy of Ibandronate can be decreased when used in combination with Omeprazole.Approved, Investigational
IbuprofenThe metabolism of Ibuprofen can be decreased when combined with Omeprazole.Approved
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Omeprazole.Approved
IfosfamideThe metabolism of Ifosfamide can be decreased when combined with Omeprazole.Approved
ImatinibThe metabolism of Omeprazole can be decreased when combined with Imatinib.Approved
ImipramineThe metabolism of Imipramine can be decreased when combined with Omeprazole.Approved
IndinavirThe serum concentration of Indinavir can be decreased when it is combined with Omeprazole.Approved
indisulamThe metabolism of indisulam can be decreased when combined with Omeprazole.Investigational
IndomethacinThe metabolism of Indomethacin can be decreased when combined with Omeprazole.Approved, Investigational
IrbesartanThe metabolism of Omeprazole can be decreased when combined with Irbesartan.Approved, Investigational
IronOmeprazole can cause a decrease in the absorption of Iron resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Iron DextranOmeprazole can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
Iron saccharateOmeprazole can cause a decrease in the absorption of Iron saccharate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
IsavuconazoniumThe metabolism of Omeprazole can be decreased when combined with Isavuconazonium.Approved, Investigational
IsoniazidThe metabolism of Omeprazole can be decreased when combined with Isoniazid.Approved
IsradipineThe metabolism of Omeprazole can be decreased when combined with Isradipine.Approved
ItraconazoleThe serum concentration of Itraconazole can be decreased when it is combined with Omeprazole.Approved, Investigational
IvacaftorThe serum concentration of Omeprazole can be increased when it is combined with Ivacaftor.Approved
IxazomibThe metabolism of Ixazomib can be decreased when combined with Omeprazole.Approved
KetamineThe metabolism of Ketamine can be decreased when combined with Omeprazole.Approved, Vet Approved
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Omeprazole.Approved, Investigational
KetoconazoleThe serum concentration of Ketoconazole can be decreased when it is combined with Omeprazole.Approved, Investigational
KetoprofenThe metabolism of Ketoprofen can be decreased when combined with Omeprazole.Approved, Vet Approved
LansoprazoleThe metabolism of Lansoprazole can be decreased when combined with Omeprazole.Approved, Investigational
LapatinibThe metabolism of Lapatinib can be decreased when combined with Omeprazole.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be decreased when it is combined with Omeprazole.Approved
LeflunomideThe metabolism of Leflunomide can be decreased when combined with Omeprazole.Approved, Investigational
LesinuradThe metabolism of Lesinurad can be decreased when combined with Omeprazole.Approved
LevomilnacipranThe metabolism of Levomilnacipran can be decreased when combined with Omeprazole.Approved
LicofeloneThe metabolism of Licofelone can be decreased when combined with Omeprazole.Investigational
LidocaineThe metabolism of Omeprazole can be decreased when combined with Lidocaine.Approved, Vet Approved
LisurideThe risk or severity of adverse effects can be increased when Lisuride is combined with Omeprazole.Approved, Investigational
LobeglitazoneThe metabolism of Omeprazole can be decreased when combined with Lobeglitazone.Approved, Investigational
LopinavirThe metabolism of Omeprazole can be decreased when combined with Lopinavir.Approved
LoratadineThe metabolism of Loratadine can be decreased when combined with Omeprazole.Approved
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Omeprazole.Approved
LornoxicamThe metabolism of Lornoxicam can be decreased when combined with Omeprazole.Approved, Investigational
LosartanThe metabolism of Omeprazole can be decreased when combined with Losartan.Approved
LovastatinThe metabolism of Omeprazole can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Omeprazole can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Omeprazole can be increased when it is combined with Lumacaftor.Approved
LumiracoxibThe metabolism of Lumiracoxib can be decreased when combined with Omeprazole.Approved, Investigational
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Omeprazole.Illicit, Investigational, Withdrawn
MacitentanThe metabolism of Macitentan can be decreased when combined with Omeprazole.Approved
ManidipineThe metabolism of Omeprazole can be decreased when combined with Manidipine.Approved, Investigational
Mefenamic acidThe metabolism of Mefenamic acid can be decreased when combined with Omeprazole.Approved
MelatoninThe metabolism of Melatonin can be decreased when combined with Omeprazole.Approved, Nutraceutical, Vet Approved
MeloxicamThe metabolism of Meloxicam can be decreased when combined with Omeprazole.Approved, Vet Approved
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Omeprazole.Investigational, Withdrawn
MeprobamateThe metabolism of Meprobamate can be decreased when combined with Omeprazole.Approved, Illicit
MesalazineThe therapeutic efficacy of Mesalazine can be decreased when used in combination with Omeprazole.Approved
MestranolThe metabolism of Mestranol can be decreased when combined with Omeprazole.Approved
MetergolineThe risk or severity of adverse effects can be increased when Metergoline is combined with Omeprazole.Experimental
MethadoneThe metabolism of Methadone can be decreased when combined with Omeprazole.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Omeprazole.Approved
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
MethsuximideThe metabolism of Methsuximide can be decreased when combined with Omeprazole.Approved
MethylergometrineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Omeprazole.Approved
MethylphenidateOmeprazole can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved, Investigational
MethylphenobarbitalThe metabolism of Methylphenobarbital can be decreased when combined with Omeprazole.Approved
MethysergideThe risk or severity of adverse effects can be increased when Methysergide is combined with Omeprazole.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Omeprazole.Approved, Investigational
MetronidazoleThe metabolism of Metronidazole can be decreased when combined with Omeprazole.Approved
MevastatinThe serum concentration of Mevastatin can be increased when it is combined with Omeprazole.Experimental
MexiletineThe metabolism of Omeprazole can be decreased when combined with Mexiletine.Approved
MidostaurinThe metabolism of Omeprazole can be decreased when combined with Midostaurin.Approved
MifepristoneThe serum concentration of Omeprazole can be increased when it is combined with Mifepristone.Approved, Investigational
MirtazapineThe metabolism of Mirtazapine can be decreased when combined with Omeprazole.Approved
MitotaneThe serum concentration of Omeprazole can be decreased when it is combined with Mitotane.Approved
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Omeprazole.Approved
ModafinilThe metabolism of Omeprazole can be decreased when combined with Modafinil.Approved, Investigational
MontelukastThe metabolism of Montelukast can be decreased when combined with Omeprazole.Approved
Mycophenolic acidThe serum concentration of Mycophenolic acid can be decreased when it is combined with Omeprazole.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Omeprazole.Approved
NaproxenThe metabolism of Naproxen can be decreased when combined with Omeprazole.Approved, Vet Approved
NateglinideThe metabolism of Nateglinide can be decreased when combined with Omeprazole.Approved, Investigational
NefazodoneThe metabolism of Omeprazole can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of the active metabolites of Nelfinavir can be reduced when Nelfinavir is used in combination with Omeprazole resulting in a loss in efficacy.Approved
NetupitantThe serum concentration of Omeprazole can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Omeprazole can be increased when combined with Nevirapine.Approved
NicardipineThe metabolism of Omeprazole can be decreased when combined with Nicardipine.Approved
NicergolineThe risk or severity of adverse effects can be increased when Nicergoline is combined with Omeprazole.Approved, Investigational
NiclosamideThe metabolism of Niclosamide can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
NicotineThe metabolism of Nicotine can be decreased when combined with Omeprazole.Approved
NilotinibThe serum concentration of Nilotinib can be decreased when it is combined with Omeprazole.Approved, Investigational
NilutamideThe metabolism of Nilutamide can be decreased when combined with Omeprazole.Approved
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Omeprazole.Approved
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Omeprazole.Approved
OlaparibThe metabolism of Omeprazole can be decreased when combined with Olaparib.Approved
OlodaterolThe metabolism of Olodaterol can be decreased when combined with Omeprazole.Approved
OndansetronThe metabolism of Ondansetron can be decreased when combined with Omeprazole.Approved
OsimertinibThe serum concentration of Omeprazole can be increased when it is combined with Osimertinib.Approved
OspemifeneThe metabolism of Ospemifene can be decreased when combined with Omeprazole.Approved
OxaprozinThe metabolism of Oxaprozin can be decreased when combined with Omeprazole.Approved
OxiconazoleThe metabolism of Oxiconazole can be decreased when combined with Omeprazole.Approved
PaclitaxelThe metabolism of Paclitaxel can be decreased when combined with Omeprazole.Approved, Vet Approved
PalbociclibThe serum concentration of Omeprazole can be increased when it is combined with Palbociclib.Approved
PamidronateThe therapeutic efficacy of Pamidronate can be decreased when used in combination with Omeprazole.Approved
PantoprazoleThe metabolism of Omeprazole can be decreased when combined with Pantoprazole.Approved
ParamethadioneThe metabolism of Paramethadione can be decreased when combined with Omeprazole.Approved
ParecoxibThe metabolism of Parecoxib can be decreased when combined with Omeprazole.Approved
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Omeprazole.Approved
Peginterferon alfa-2bThe serum concentration of Omeprazole can be increased when it is combined with Peginterferon alfa-2b.Approved
PentamidineThe metabolism of Pentamidine can be decreased when combined with Omeprazole.Approved
PentobarbitalThe metabolism of Omeprazole can be increased when combined with Pentobarbital.Approved, Vet Approved
PergolideThe risk or severity of adverse effects can be increased when Pergolide is combined with Omeprazole.Approved, Investigational, Vet Approved, Withdrawn
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Omeprazole.Approved
PethidineThe metabolism of Pethidine can be decreased when combined with Omeprazole.Approved
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Omeprazole.Withdrawn
PhenindioneThe serum concentration of Phenindione can be increased when it is combined with Omeprazole.Approved, Investigational
PhenobarbitalThe metabolism of Omeprazole can be increased when combined with Phenobarbital.Approved
PhenprocoumonThe serum concentration of Phenprocoumon can be increased when it is combined with Omeprazole.Approved, Investigational
PhenylbutazoneThe metabolism of Phenylbutazone can be decreased when combined with Omeprazole.Approved, Vet Approved
PhenytoinThe serum concentration of Omeprazole can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PioglitazoneThe metabolism of Pioglitazone can be decreased when combined with Omeprazole.Approved, Investigational
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Omeprazole.Approved, Investigational
PiroxicamThe metabolism of Piroxicam can be decreased when combined with Omeprazole.Approved, Investigational
PitavastatinThe metabolism of Pitavastatin can be decreased when combined with Omeprazole.Approved
PodofiloxThe metabolism of Podofilox can be decreased when combined with Omeprazole.Approved
PosaconazoleThe serum concentration of Posaconazole can be decreased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
PrasugrelThe metabolism of Prasugrel can be decreased when combined with Omeprazole.Approved
PravastatinThe metabolism of Pravastatin can be decreased when combined with Omeprazole.Approved
PraziquantelThe metabolism of Praziquantel can be decreased when combined with Omeprazole.Approved, Vet Approved
PrimidoneThe metabolism of Omeprazole can be increased when combined with Primidone.Approved, Vet Approved
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Omeprazole.Approved, Vet Approved
ProguanilThe metabolism of Proguanil can be decreased when combined with Omeprazole.Approved
PromazineThe metabolism of Promazine can be decreased when combined with Omeprazole.Approved, Vet Approved
PropofolThe metabolism of Propofol can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
PropranololThe metabolism of Propranolol can be decreased when combined with Omeprazole.Approved, Investigational
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Omeprazole.Approved
PyrimethamineThe metabolism of Omeprazole can be decreased when combined with Pyrimethamine.Approved, Vet Approved
QuazepamThe metabolism of Quazepam can be decreased when combined with Omeprazole.Approved, Illicit
QuetiapineThe metabolism of Quetiapine can be decreased when combined with Omeprazole.Approved
QuinidineThe metabolism of Quinidine can be decreased when combined with Omeprazole.Approved
QuinineThe metabolism of Quinine can be decreased when combined with Omeprazole.Approved
RabeprazoleThe metabolism of Rabeprazole can be decreased when combined with Omeprazole.Approved, Investigational
RaltegravirThe serum concentration of Raltegravir can be increased when it is combined with Omeprazole.Approved
RamelteonThe metabolism of Ramelteon can be decreased when combined with Omeprazole.Approved, Investigational
RanitidineThe metabolism of Ranitidine can be decreased when combined with Omeprazole.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Omeprazole.Approved, Investigational
RifabutinThe metabolism of Omeprazole can be increased when combined with Rifabutin.Approved
RifampicinThe serum concentration of Omeprazole can be decreased when it is combined with Rifampicin.Approved
RifapentineThe metabolism of Omeprazole can be increased when combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Omeprazole.Approved, Investigational
RilpivirineThe serum concentration of Rilpivirine can be decreased when it is combined with Omeprazole.Approved
RiociguatThe serum concentration of Riociguat can be decreased when it is combined with Omeprazole.Approved
RisedronateThe serum concentration of Risedronate can be increased when it is combined with Omeprazole.Approved, Investigational
RofecoxibThe metabolism of Rofecoxib can be decreased when combined with Omeprazole.Investigational, Withdrawn
RomidepsinThe metabolism of Romidepsin can be decreased when combined with Omeprazole.Approved, Investigational
RopiniroleThe metabolism of Omeprazole can be decreased when combined with Ropinirole.Approved, Investigational
RosiglitazoneThe metabolism of Rosiglitazone can be decreased when combined with Omeprazole.Approved, Investigational
RosuvastatinThe metabolism of Rosuvastatin can be decreased when combined with Omeprazole.Approved
RupatadineThe metabolism of Rupatadine can be decreased when combined with Omeprazole.Approved
Salicylic acidThe metabolism of Salicylic acid can be decreased when combined with Omeprazole.Approved, Vet Approved
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Omeprazole.Approved, Investigational
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Omeprazole.Approved
SecobarbitalThe metabolism of Omeprazole can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineThe metabolism of Selegiline can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Omeprazole.Approved
SertralineThe metabolism of Sertraline can be decreased when combined with Omeprazole.Approved
SildenafilThe metabolism of Omeprazole can be decreased when combined with Sildenafil.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Omeprazole.Approved
SiltuximabThe serum concentration of Omeprazole can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Omeprazole can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Omeprazole.Approved
SitaxentanThe metabolism of Sitaxentan can be decreased when combined with Omeprazole.Approved, Investigational, Withdrawn
SorafenibThe metabolism of Omeprazole can be decreased when combined with Sorafenib.Approved, Investigational
St. John's WortThe serum concentration of Omeprazole can be decreased when it is combined with St. John's Wort.Investigational, Nutraceutical
StiripentolThe serum concentration of Omeprazole can be increased when it is combined with Stiripentol.Approved
SulfadiazineThe metabolism of Omeprazole can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Omeprazole can be decreased when combined with Sulfamethoxazole.Approved
SulfamoxoleThe metabolism of Sulfamoxole can be decreased when combined with Omeprazole.Approved
SulfinpyrazoneThe metabolism of Sulfinpyrazone can be decreased when combined with Omeprazole.Approved
SulfisoxazoleThe metabolism of Omeprazole can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SuprofenThe metabolism of Suprofen can be decreased when combined with Omeprazole.Approved, Withdrawn
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Omeprazole.Approved, Investigational
TamoxifenThe metabolism of Tamoxifen can be decreased when combined with Omeprazole.Approved
TapentadolThe metabolism of Tapentadol can be decreased when combined with Omeprazole.Approved
Technetium Tc-99m etidronateThe therapeutic efficacy of Technetium Tc-99m etidronate can be decreased when used in combination with Omeprazole.Approved
Technetium Tc-99m medronateThe therapeutic efficacy of Technetium Tc-99m medronate can be decreased when used in combination with Omeprazole.Approved
TelaprevirThe metabolism of Omeprazole can be decreased when combined with Telaprevir.Approved, Withdrawn
TelithromycinThe metabolism of Omeprazole can be decreased when combined with Telithromycin.Approved
TemazepamThe metabolism of Temazepam can be decreased when combined with Omeprazole.Approved
TeniposideThe metabolism of Teniposide can be decreased when combined with Omeprazole.Approved
Tenofovir disoproxilThe metabolism of Omeprazole can be decreased when combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamThe metabolism of Tenoxicam can be decreased when combined with Omeprazole.Approved
TerbinafineThe metabolism of Terbinafine can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Omeprazole.Withdrawn
TergurideThe risk or severity of adverse effects can be increased when Terguride is combined with Omeprazole.Experimental
TeriflunomideThe serum concentration of Omeprazole can be decreased when it is combined with Teriflunomide.Approved
TestosteroneThe metabolism of Testosterone can be decreased when combined with Omeprazole.Approved, Investigational
ThalidomideThe metabolism of Thalidomide can be decreased when combined with Omeprazole.Approved, Investigational, Withdrawn
TheophyllineThe metabolism of Omeprazole can be decreased when combined with Theophylline.Approved
ThiamylalThe metabolism of Thiamylal can be decreased when combined with Omeprazole.Approved, Vet Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Omeprazole.Approved, Withdrawn
TicagrelorThe metabolism of Omeprazole can be decreased when combined with Ticagrelor.Approved
TiclopidineThe metabolism of Omeprazole can be decreased when combined with Ticlopidine.Approved
Tiludronic acidThe therapeutic efficacy of Tiludronic acid can be decreased when used in combination with Omeprazole.Approved, Investigational, Vet Approved
TimololThe metabolism of Timolol can be decreased when combined with Omeprazole.Approved
TioclomarolThe serum concentration of Tioclomarol can be increased when it is combined with Omeprazole.Experimental
TipranavirThe serum concentration of Omeprazole can be decreased when it is combined with Tipranavir.Approved, Investigational
TizanidineThe serum concentration of Tizanidine can be increased when it is combined with Omeprazole.Approved
TocilizumabThe serum concentration of Omeprazole can be decreased when it is combined with Tocilizumab.Approved
TofacitinibThe metabolism of Tofacitinib can be decreased when combined with Omeprazole.Approved, Investigational
TolbutamideThe metabolism of Omeprazole can be decreased when combined with Tolbutamide.Approved
TolterodineThe metabolism of Tolterodine can be decreased when combined with Omeprazole.Approved, Investigational
TopiramateThe metabolism of Omeprazole can be decreased when combined with Topiramate.Approved
TopiroxostatThe metabolism of Omeprazole can be decreased when combined with Topiroxostat.Approved, Investigational
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Omeprazole.Approved, Investigational
TorasemideThe metabolism of Torasemide can be decreased when combined with Omeprazole.Approved
TrabectedinThe metabolism of Trabectedin can be decreased when combined with Omeprazole.Approved, Investigational
TranylcypromineThe metabolism of Omeprazole can be decreased when combined with Tranylcypromine.Approved
TreprostinilThe metabolism of Treprostinil can be decreased when combined with Omeprazole.Approved, Investigational
TretinoinThe metabolism of Tretinoin can be decreased when combined with Omeprazole.Approved, Investigational, Nutraceutical
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Omeprazole.Approved
TrimethoprimThe metabolism of Trimethoprim can be decreased when combined with Omeprazole.Approved, Vet Approved
TrimipramineThe metabolism of Trimipramine can be decreased when combined with Omeprazole.Approved
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Omeprazole.Investigational, Withdrawn
UbidecarenoneThe serum concentration of Ubidecarenone can be increased when it is combined with Omeprazole.Approved, Investigational, Nutraceutical
ValdecoxibThe metabolism of Valdecoxib can be decreased when combined with Omeprazole.Investigational, Withdrawn
Valproic AcidThe metabolism of Valproic Acid can be decreased when combined with Omeprazole.Approved, Investigational
ValsartanThe metabolism of Valsartan can be decreased when combined with Omeprazole.Approved, Investigational
VenlafaxineThe metabolism of Omeprazole can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Omeprazole can be decreased when combined with Verapamil.Approved
VicrivirocThe metabolism of Vicriviroc can be decreased when combined with Omeprazole.Investigational
VincristineThe serum concentration of Vincristine can be increased when it is combined with Omeprazole.Approved, Investigational
VismodegibThe metabolism of Vismodegib can be decreased when combined with Omeprazole.Approved
VoriconazoleThe serum concentration of Omeprazole can be increased when it is combined with Voriconazole.Approved, Investigational
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Omeprazole.Approved
WarfarinThe serum concentration of Warfarin can be increased when it is combined with Omeprazole.Approved
XimelagatranThe metabolism of Ximelagatran can be decreased when combined with Omeprazole.Approved, Investigational, Withdrawn
ZafirlukastThe metabolism of Omeprazole can be decreased when combined with Zafirlukast.Approved, Investigational
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Omeprazole.Approved, Investigational
ZaltoprofenThe metabolism of Zaltoprofen can be decreased when combined with Omeprazole.Approved, Investigational
ZidovudineThe metabolism of Zidovudine can be decreased when combined with Omeprazole.Approved
ZileutonThe metabolism of Zileuton can be decreased when combined with Omeprazole.Approved, Investigational, Withdrawn
ZiprasidoneThe metabolism of Omeprazole can be decreased when combined with Ziprasidone.Approved
Zoledronic acidThe therapeutic efficacy of Zoledronic acid can be decreased when used in combination with Omeprazole.Approved
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Omeprazole.Approved
ZopicloneThe metabolism of Zopiclone can be decreased when combined with Omeprazole.Approved
ZucapsaicinThe metabolism of Omeprazole can be decreased when combined with Zucapsaicin.Approved
Food Interactions
  • Avoid alcohol.
  • Take 30-60 minutes before meals.

References

Synthesis Reference

Arne E. Brandstrom, Bo R. Lamm, "Processes for the preparation of omeprazole and intermediates therefore." U.S. Patent US4620008, issued October, 1982.

US4620008
General References
  1. Yang YX, Lewis JD, Epstein S, Metz DC: Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA. 2006 Dec 27;296(24):2947-53. [PubMed:17190895]
External Links
Human Metabolome Database
HMDB01913
KEGG Drug
D00455
KEGG Compound
C07324
PubChem Compound
4594
PubChem Substance
46509065
ChemSpider
4433
BindingDB
50241343
ChEBI
77260
ChEMBL
CHEMBL1503
Therapeutic Targets Database
DAP000180
PharmGKB
PA450704
IUPHAR
4279
Guide to Pharmacology
GtP Drug Page
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Omeprazole
ATC Codes
A02BD05 — Omeprazole, amoxicillin and clarithromycinA02BD01 — Omeprazole, amoxicillin and metronidazoleA02BC01 — Omeprazole
AHFS Codes
  • 56:28.36 — Proton-pump Inhibitors
FDA label
Download (218 KB)
MSDS
Download (73.8 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedBasic ScienceHealthy Volunteers2
0CompletedPreventionLong Segment Barrett's Esophagus / Short Segment Barrett's Esophagus1
0WithdrawnTreatmentEsophagitis1
1Active Not RecruitingBasic ScienceDrug-Drug Interaction (DDI)1
1Active Not RecruitingOtherHealthy Volunteers1
1Active Not RecruitingOtherNeoplasms1
1Active Not RecruitingTreatmentNeoplasms1
1CompletedNot AvailableAlzheimer's Disease (AD) / Huntington's Disease (HD)1
1CompletedNot AvailableClostridium Difficile Infection (CDI) / Healthy Volunteers1
1CompletedNot AvailableDrug Interactions1
1CompletedNot AvailableGastric Acid-related Disorders / HCV Infections1
1CompletedNot AvailableHealthy Volunteers5
1CompletedNot AvailableHuman Immunodeficiency Virus (HIV) Infections1
1CompletedNot AvailablePain, Chronic1
1CompletedNot AvailablePharmacodynamics Study1
1CompletedNot AvailableTumors, Solid1
1CompletedBasic Science(t1/2,λz) / Cmax / Pharmacokinetics / Plasma [AUC(0-672)] / Plasma [AUC(0-t)] / Plasma AUC / Tmax1
1CompletedBasic ScienceAlzheimer's Disease (AD) / Metabolism1
1CompletedBasic ScienceAtopic Dermatitis (AD)1
1CompletedBasic ScienceBioequivalence, AUC, Cmax, Pharmacokinetics1
1CompletedBasic ScienceDrug Interactions1
1CompletedBasic ScienceEvaluation of Pharmacokinetics of Sativex in the Absence and Presence of a CYP2C19 Inhibitor / Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a Known Inducer of CYP3A4 / Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a Potent Inhibitor of CYP3A41
1CompletedBasic ScienceGastric Ulcer (GU)1
1CompletedBasic ScienceHealthy Volunteers8
1CompletedBasic ScienceHealthy Volunteers / Pharmacologic Actions1
1CompletedBasic SciencePharmacodynamics of ASP8477 / Pharmacokinetics of ASP84771
1CompletedBasic SciencePharmacokinetic Assessments in Healthy Volunteers1
1CompletedBasic ScienceReflux Esophagitis (RE)1
1CompletedBasic ScienceRheumatoid Arthritis2
1CompletedDiagnosticCytochrome / Pharmacokinetics1
1CompletedDiagnosticDrug Interactions1
1CompletedDiagnosticHealthy Volunteers1
1CompletedHealth Services ResearchHealthy Volunteers1
1CompletedSupportive CareHealthy Volunteers1
1CompletedTreatmentAcid Reflux / Gastro Oesophageal Reflux Disease1
1CompletedTreatmentAdult Solid Neoplasm1
1CompletedTreatmentAdvanced Solid Tumors, Excluding Breast Cancer1
1CompletedTreatmentAnemias / Healthy Volunteers1
1CompletedTreatmentCastration Resistant Prostate Cancer (CRPC) / Pharmacokinetics of MDV31001
1CompletedTreatmentChronic Hepatitis C Infection1
1CompletedTreatmentCrohn's Disease (CD)1
1CompletedTreatmentDiabetes Mellitus (DM) / Healthy Volunteers1
1CompletedTreatmentDrug Interaction of Clopidogrel1
1CompletedTreatmentDrug Interactions1
1CompletedTreatmentErectile Dysfunction (ED)1
1CompletedTreatmentGastric Ulcer (GU) / Reflux, Gastroesophageal1
1CompletedTreatmentHealthy Volunteers27
1CompletedTreatmentHeartburn1
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections1
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Infection, Human Immunodeficiency Virus I1
1CompletedTreatmentInfectious Diseases1
1CompletedTreatmentNon-Hodgkin's Lymphoma (NHL) / Tumors1
1CompletedTreatmentPsoriasis2
1CompletedTreatmentReflux, Gastroesophageal1
1CompletedTreatmentTumors, Solid2
1Not Yet RecruitingOtherCrohn's Disease (CD)1
1Not Yet RecruitingTreatmentTumors, Solid1
1RecruitingTreatmentAdvanced Solid Tumors / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Mantle Cell Lymphoma (MCL) / Marginal Zone Lymphoma / Primary Mediastinal Lymphoma1
1RecruitingTreatmentBreast Neoplasm, Male / Neoplasms, Breast1
1RecruitingTreatmentGastro Esophageal Reflux Disorder / Gastroesophageal Reflux Disorder1
1RecruitingTreatmentHealthy Volunteers1
1Unknown StatusTreatmentGlaucoma1
1WithdrawnTreatmentHealthy Volunteers1
1WithdrawnTreatmentLaryngomalacia1
1WithdrawnTreatmentObstructive Sleep Apnea (OSA) / Reflux, Gastroesophageal / Upper Airway Resistance Syndrome1
1WithdrawnTreatmentTumors, Solid1
1, 2CompletedTreatmentAutism Spectrum Conditions/Disorders / Gastrointestinal Problems1
1, 2CompletedTreatmentBacterial Infection Due to Helicobacter Pylori (H. Pylori)1
1, 2CompletedTreatmentCentral Serous Chorioretinopathy (CSC)1
1, 2CompletedTreatmentUlcerative Colitis (UC)1
1, 2RecruitingTreatmentCrohn's Disease (CD)1
2Active Not RecruitingTreatmentIntestinal Colonization With Multidrug-resistant Bacteria1
2CompletedNot AvailableReflux, Gastroesophageal1
2CompletedTreatmentColorectal Cancers1
2CompletedTreatmentDuodenal Ulcer1
2CompletedTreatmentFatty Liver / Insulin Resistance / Liver Dysfunction1
2CompletedTreatmentGastrinoma / Zollinger-Ellison Syndrome1
2CompletedTreatmentGastroesophageal Reflux Disease (GERD)1
2CompletedTreatmentIdiopathic Pulmonary Fibrosis (IPF)1
2CompletedTreatmentMalignant Lymphomas2
2CompletedTreatmentNonalcoholic Steatohepatitis1
2CompletedTreatmentSquamous Cell Carcinoma of the Head and Neck (SCCHN)1
2Not Yet RecruitingTreatmentNAFLD / NASH - Nonalcoholic Steatohepatitis / Type 2 Diabetes Mellitus1
2Not Yet RecruitingTreatmentNon-erosive Reflux Disease (NERD)1
2RecruitingTreatmentCancer of the Breast1
2RecruitingTreatmentCervical Squamous Cell Carcinoma In Situ / Vulvar High Grade Squamous Intraepithelial Lesion1
2RecruitingTreatmentSquamous Cell Carcinoma of the Oral Cavity1
2TerminatedTreatmentIndigestion1
2WithdrawnTreatmentCancer of Head and Neck1
2WithdrawnTreatmentContact Ulcer of Vocal Folds / Granuloma / Granuloma of Vocal Cords / Granuloma, Laryngeal1
2, 3CompletedTreatmentNon-erosive Reflux Disease (NERD)1
3Active Not RecruitingTreatmentMyocardial Injury After Noncardiac Surgery (MINS)1
3CompletedNot AvailableGastric Acid / Human Experimentation2
3CompletedNot AvailableIntragastric Acidity1
3CompletedPreventionAnkylosing Spondylitis (AS) / Osteoarthritis (OA) / Rheumatoid Arthritis1
3CompletedPreventionPrecancerous Gastric Lesions1
3CompletedTreatmentAspirin-Associated Gastric Ulcers1
3CompletedTreatmentBacterial Infection Due to Helicobacter Pylori (H. Pylori)1
3CompletedTreatmentBleeding Peptic Ulcers Disease1
3CompletedTreatmentDuodenal Ulcer1
3CompletedTreatmentErosive Esophagitis(EE)1
3CompletedTreatmentExocrine Pancreatic Insufficiency / Pancreatitis, Chronic / Post-pancreatectomy1
3CompletedTreatmentGERD1
3CompletedTreatmentGastric Ulcer (GU)3
3CompletedTreatmentGastroesophageal Reflux Disease / Heartburn1
3CompletedTreatmentHelicobacter Infections1
3CompletedTreatmentHemorrhage, Gastrointestinal1
3CompletedTreatmentHuman Experimentation1
3CompletedTreatmentNeurocysticercosis1
3CompletedTreatmentNon-erosive Reflux Disease (NERD)2
3CompletedTreatmentPeptic Ulcers / Upper Gastrointestinal Hemorrhage1
3CompletedTreatmentPeptic ulcer haemorrhage1
3CompletedTreatmentReflux Esophagitis (RE)2
3CompletedTreatmentReflux, Gastroesophageal1
3RecruitingTreatmentBacterial Infection Due to Helicobacter Pylori (H. Pylori) / Indigestion1
3RecruitingTreatmentGlobus1
3RecruitingTreatmentHelicobacter-associated Gastritis1
3RecruitingTreatmentIndigestion1
3RecruitingTreatmentNon-Bleeding Peptic Ulcers1
3TerminatedHealth Services ResearchCoughing1
3TerminatedTreatmentHelicobacter Infections / Motor Fluctuations / Parkinson's Disease (PD)1
3Unknown StatusPreventionEsophagus, Barrett1
3Unknown StatusTreatmentGastroesophageal Reflux Disease (GERD)1
3Unknown StatusTreatmentMalignant Neoplasm of Stomach1
3WithdrawnTreatmentDiabetes, Diabetes Mellitus Type 11
4Active Not RecruitingTreatmentGERD Gastroesophageal Reflux Disease1
4Active Not RecruitingTreatmentGout Acute1
4CompletedNot AvailableAchlorhydria / Bone destruction / GERD / Hip Fractures1
4CompletedNot AvailableNormal Healthy Subject Population1
4CompletedBasic ScienceHealthy Volunteers1
4CompletedBasic ScienceRejection, Transplant1
4CompletedDiagnosticBacterial Infection Due to Helicobacter Pylori (H. Pylori)1
4CompletedDiagnosticFood Allergy1
4CompletedDiagnosticGastroesophageal Reflux Disease1
4CompletedDiagnosticLaryngopharyngeal Reflux (LPR)1
4CompletedPreventionMarginal Ulcers1
4CompletedSupportive CareOther Surgical Procedures / Pain1
4CompletedTreatmentChronic Rhinosinusitis (Diagnosis) / Laryngopharyngeal Reflux1
4CompletedTreatmentCompliance / Depression / Indigestion1
4CompletedTreatmentCoronary Artery Disease / Drug Interaction Potentiation / VA Drug Interactions [VA Drug Interaction]1
4CompletedTreatmentErosive Esophagitis(EE)1
4CompletedTreatmentEsophagus, Barrett / Inflammatory Reaction1
4CompletedTreatmentGERD1
4CompletedTreatmentGastric Ulcer (GU)1
4CompletedTreatmentHealthy Volunteers1
4CompletedTreatmentHeartburn1
4CompletedTreatmentHemorrhage / Peptic Ulcers1
4CompletedTreatmentHypoalbuminemia / Peptic Ulcer Bleeding1
4CompletedTreatmentOsteoarthritis (OA) / Rheumatoid Arthritis1
4CompletedTreatmentPeptic Ulcers1
4Not Yet RecruitingBasic ScienceProbiotics1
4Not Yet RecruitingTreatmentEPS / GERD1
4Not Yet RecruitingTreatmentGastroduodenal Ulcers / Marginal Ulcers / Peptic ulcer haemorrhage1
4RecruitingBasic ScienceTolerance1
4RecruitingBasic ScienceType 2 Diabetes Mellitus1
4RecruitingTreatmentChronic Low Back Pain (CLBP)2
4RecruitingTreatmentCrohn's Disease (CD) / Ulcerative Colitis (UC)1
4RecruitingTreatmentHeartburn1
4RecruitingTreatmentLaryngopharyngeal Reflux1
4RecruitingTreatmentTinea Cruris / Tinea Pedis1
4SuspendedTreatmentRotator Cuff Syndrome1
4TerminatedPreventionLaryngopharyngeal Reflux / Throat Pain1
4TerminatedTreatmentPeptic ulcer haemorrhage1
4TerminatedTreatmentReflux, Gastroesophageal1
4Unknown StatusPreventionAcute Coronary Syndromes (ACS)1
4Unknown StatusTreatmentCDA Type I1
4Unknown StatusTreatmentCoronary Artery Disease1
4Unknown StatusTreatmentGERD1
4Unknown StatusTreatmentH. Pylori Infection1
4Unknown StatusTreatmentNonvariceal Upper Gastrointestinal Bleeding1
4WithdrawnPreventionPeptic Ulcers1
4WithdrawnTreatmentCoronary Artery Disease1
4WithdrawnTreatmentEustachian Tube Dysfunction / Laryngopharyngeal Reflux1
Not AvailableActive Not RecruitingNot AvailableGastroduodenal Ulcers / Marginal Ulcers / Peptic ulcer haemorrhage1
Not AvailableCompletedNot AvailableAnthocyanin Metabolism1
Not AvailableCompletedNot AvailableAspirin Blood Level / Proton Pump Inhiditor Treatment1
Not AvailableCompletedNot AvailableChronic Laryngitis / Gastroesophageal Reflux Disease (GERD)1
Not AvailableCompletedNot AvailableCommunity Acquired Pneumonia (CAP) / Gastroesophageal Reflux Disease (GERD)1
Not AvailableCompletedBasic ScienceGastroesophageal Reflux Disease1
Not AvailableCompletedDiagnosticHealthy Volunteers / Liver Cirrhosis1
Not AvailableCompletedTreatmentBacterial Infection Due to Helicobacter Pylori (H. Pylori)2
Not AvailableCompletedTreatmentBacterial Infection Due to Helicobacter Pylori (H. Pylori) / Functional Dyspepsia1
Not AvailableCompletedTreatmentGastric MALT Lymphoma1
Not AvailableCompletedTreatmentMetabolism of Clopidogrel1
Not AvailableRecruitingNot AvailableDepression1
Not AvailableRecruitingBasic ScienceClostridium Difficile Infection (CDI)1
Not AvailableRecruitingDiagnosticBile Reflux / Gastroesophageal Reflux Disease / Indigestion1
Not AvailableRecruitingDiagnosticNon-erosive Reflux Disease (NERD) / Reflux, Gastroesophageal1
Not AvailableTerminatedScreeningCytochrome P450 Phenotype and Genotype Metrics1
Not AvailableUnknown StatusTreatmentEsophagus, Barrett / Reflux, Gastroesophageal1
Not AvailableWithdrawnDiagnosticGastroesophageal Reflux Disease / Indigestion / Non Erosive Reflux Disease1

Pharmacoeconomics

Manufacturers
  • Apotex inc
  • Dr reddys laboratories ltd
  • Impax laboratories inc
  • Kremers urban development co
  • Lek pharmaceuticals d d
  • Mylan pharmaceuticals inc
  • Sandoz inc
  • Watson laboratories inc florida
  • Astrazeneca lp
  • Dexcel pharma technologies ltd
  • Santarus, Inc.
Packagers
Dosage forms
FormRouteStrength
Capsule, delayed releaseOral20 mg
Tablet, delayed releaseOral10 mg
Tablet, delayed releaseOral20 mg
Capsule, delayed releaseOral40 mg
Kit
CapsuleOral10 mg/1
CapsuleOral20 mg/1
CapsuleOral40 mg/1
Capsule, delayed releaseOral10 mg/1
Capsule, delayed releaseOral20 mg/1
Capsule, delayed releaseOral40 mg/1
Capsule, delayed release pelletsOral10 mg/1
Capsule, delayed release pelletsOral20 mg/1
Capsule, delayed release pelletsOral40 mg/1
Capsule, gelatin coatedOral
Powder, for suspensionOral
Tablet, delayed releaseOral20 mg/1
CapsuleOral20.6 mg/1
Capsule, delayed releaseOral20.6 mg/1
Granule, delayed releaseOral10 mg/1
Granule, delayed releaseOral2.5 mg/1
Tablet, delayed releaseOral20.6 mg/1
Capsule, delayed releaseOral10 mg
Tablet, film coatedOral
CapsuleOral
Prices
Unit descriptionCostUnit
PriLOSEC 30 20 mg Delayed Release Capsule Bottle459.99USD bottle
Zegerid 30 20-1680 mg Packets Packet224.27USD packet
Zegerid 30 40-1680 mg Packets Packet224.27USD packet
PriLOSEC 30 10 mg Delayed Release Capsule Bottle174.37USD bottle
Omeprazole 28 20 mg Enteric Coated Tabs Box25.99USD box
PriLOSEC OTC 14 20 mg Enteric Coated Tabs Box19.99USD box
PriLOSEC 40 mg Delayed Release Capsule9.59USD capsule
Prilosec dr 40 mg capsule9.22USD capsule
Omeprazole 40 mg Delayed Release Capsule7.69USD capsule
Zegerid 40-1100 mg capsule7.48USD capsule
Zegerid 20 mg capsule7.19USD capsule
Zegerid 40 mg capsule6.46USD capsule
Prilosec dr 20 mg capsule6.24USD capsule
Prilosec 20 mg capsule dr6.15USD capsule
Prilosec dr 10 mg capsule5.59USD capsule
Omeprazole powder5.05USD g
Omeprazole 20 mg Delayed Release Capsule4.32USD capsule
Omeprazole 10 mg Delayed Release Capsule3.13USD capsule
Losec (Sustained-Release Tablet) 20 mg Capsule/Sustained Release Tablet2.48USD tablet
Losec (Sustained-Release Tablet) 10 mg Capsule/Sustained Release Tablet1.97USD tablet
Losec (Sustained-Release Capsule) 20 mg Capsule/Sustained Release Tablet1.24USD tablet
Apo-Omeprazole 20 mg Capsule/Sustained Release Tablet1.15USD tablet
Mylan-Omeprazole 20 mg Capsule/Sustained Release Tablet1.15USD tablet
Pms-Omeprazole (Delayed Release Tablet) 20 mg Capsule/Sustained Release Tablet1.15USD tablet
Pms-Omeprazole (Sustained-Release Capsule) 20 mg Capsule/Sustained Release Tablet1.15USD tablet
Ratio-Omeprazole (Sustained-Release Tablet) 20 mg Capsule/Sustained Release Tablet1.15USD tablet
Sandoz Omeprazole (Sustained-Release Capsule) 20 mg Capsule/Sustained Release Tablet1.15USD tablet
Mylan-Omeprazole 10 mg Capsule/Sustained Release Tablet0.86USD tablet
Sandoz Omeprazole (Sustained-Release Capsule) 10 mg Capsule/Sustained Release Tablet0.86USD tablet
Zegerid otc 20-1100 mg capsule0.78USD capsule
Prilosec otc 20 mg tablet0.76USD tablet
Omeprazole dr 20 mg tablet0.66USD tablet
CVS Pharmacy omeprazole dr 20 mg tablet0.53USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5690960No1994-11-252014-11-25Us
CA2180535No2004-03-232014-01-05Canada
CA1338377No1996-06-112013-06-11Canada
US6489346No1996-07-162016-07-16Us
US6699885No1996-07-162016-07-16Us
USRE45198No1996-07-162016-07-16Us
US6645988No1996-07-162016-07-16Us
US7399772No1996-07-162016-07-16Us
US6150380Yes1999-05-102019-05-10Us
US6191148Yes1999-04-092019-04-09Us
US6147103Yes1999-04-092019-04-09Us
US6166213Yes1999-04-092019-04-09Us
US5900424Yes1996-11-042016-11-04Us
US6428810Yes2000-05-032020-05-03Us
US9023391No2005-08-162025-08-16Us
US6403616No1999-11-152019-11-15Us
US5817338No1995-10-062015-10-06Us
US5840737No1996-07-152016-07-15Us
US6780882No1996-07-152016-07-15Us
US6926907No2003-02-282023-02-28Us
US9539214No2013-03-132033-03-13Us
US9364439No2002-05-312022-05-31Us
US8206741No2003-02-282023-02-28Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)155 °CFDA label
water solubilityVery slightly soluble FDA label
logP2.23SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility0.359 mg/mLALOGPS
logP1.66ALOGPS
logP2.43ChemAxon
logS-3ALOGPS
pKa (Strongest Acidic)9.29ChemAxon
pKa (Strongest Basic)4.77ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area77.1 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity93.66 m3·mol-1ChemAxon
Polarizability37.45 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9968
Blood Brain Barrier-0.6326
Caco-2 permeable+0.8867
P-glycoprotein substrateNon-substrate0.5573
P-glycoprotein inhibitor IInhibitor0.6622
P-glycoprotein inhibitor IINon-inhibitor0.968
Renal organic cation transporterNon-inhibitor0.542
CYP450 2C9 substrateNon-substrate0.7838
CYP450 2D6 substrateSubstrate0.6175
CYP450 3A4 substrateSubstrate0.6901
CYP450 1A2 substrateInhibitor0.7505
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorInhibitor0.8994
CYP450 3A4 inhibitorInhibitor0.796
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.7895
Ames testNon AMES toxic0.5692
CarcinogenicityNon-carcinogens0.8318
BiodegradationNot ready biodegradable0.9778
Rat acute toxicity2.2254 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.719
hERG inhibition (predictor II)Non-inhibitor0.8977
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-002f-0900000000-412912cbbcdbd1b34699
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0002-0901000000-189e81fb724041d50498
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0f6t-0900000000-db101d248a4e861d4c3b
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0uds-0900000000-f579fb74ac97c56dd3eb
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-000i-0900000000-eefbf9686f0313da581e
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-000i-0900000000-363d6954875894f433ba
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0f6t-1900000000-d8c64d496f1d9b3ed465
MS/MS Spectrum - , positiveLC-MS/MSsplash10-014i-1669000000-51f9342d7e4bbd0356b2
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0f6t-0900000000-d21755acc44ff2d29cfa
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0f80-2900000000-9989d19c171c612ea3dc
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0002-0900000000-f74adb7f41e2d390b602
1H NMR Spectrum1D NMRNot Applicable
[1H,13C] 2D NMR Spectrum2D NMRNot Applicable

Taxonomy

Description
This compound belongs to the class of organic compounds known as sulfinylbenzimidazoles. These are polycyclic aromatic compounds containing a sulfinyl group attached at the position 2 of a benzimidazole moiety.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzimidazoles
Sub Class
Sulfinylbenzimidazoles
Direct Parent
Sulfinylbenzimidazoles
Alternative Parents
Anisoles / Methylpyridines / Alkyl aryl ethers / Imidazoles / Heteroaromatic compounds / Sulfoxides / Sulfinyl compounds / Azacyclic compounds / Organopnictogen compounds / Organonitrogen compounds
show 2 more
Substituents
Sulfinylbenzimidazole / Anisole / Alkyl aryl ether / Methylpyridine / Pyridine / Benzenoid / Azole / Imidazole / Heteroaromatic compound / Sulfoxide
show 12 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
aromatic ether, sulfoxide, pyridines, benzimidazoles (CHEBI:77260)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Sodium:potassium-exchanging atpase activity
Specific Function
Catalyzes the hydrolysis of ATP coupled with the exchange of H(+) and K(+) ions across the plasma membrane. Responsible for acid production in the stomach.
Gene Name
ATP4A
Uniprot ID
P20648
Uniprot Name
Potassium-transporting ATPase alpha chain 1
Molecular Weight
114117.74 Da
References
  1. Tajima A, Koizumi K, Suzuki K, Higashi N, Takahashi M, Shimada T, Terano A, Hiraishi H, Kuwayama H: Proton pump inhibitors and recurrent bleeding in peptic ulcer disease. J Gastroenterol Hepatol. 2008 Dec;23 Suppl 2:S237-41. doi: 10.1111/j.1440-1746.2008.05557.x. [PubMed:19120905]
  2. Shi S, Klotz U: Proton pump inhibitors: an update of their clinical use and pharmacokinetics. Eur J Clin Pharmacol. 2008 Oct;64(10):935-51. doi: 10.1007/s00228-008-0538-y. Epub 2008 Aug 5. [PubMed:18679668]
  3. Kirchheiner J, Glatt S, Fuhr U, Klotz U, Meineke I, Seufferlein T, Brockmoller J: Relative potency of proton-pump inhibitors-comparison of effects on intragastric pH. Eur J Clin Pharmacol. 2009 Jan;65(1):19-31. doi: 10.1007/s00228-008-0576-5. Epub 2008 Oct 17. [PubMed:18925391]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Transcription regulatory region dna binding
Specific Function
Ligand-activated transcriptional activator. Binds to the XRE promoter region of genes it activates. Activates the expression of multiple phase I and II xenobiotic chemical metabolizing enzyme genes...
Gene Name
AHR
Uniprot ID
P35869
Uniprot Name
Aryl hydrocarbon receptor
Molecular Weight
96146.705 Da
References
  1. Dzeletovic N, McGuire J, Daujat M, Tholander J, Ema M, Fujii-Kuriyama Y, Bergman J, Maurel P, Poellinger L: Regulation of dioxin receptor function by omeprazole. J Biol Chem. 1997 May 9;272(19):12705-13. [PubMed:9139728]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Foti RS, Wahlstrom JL: CYP2C19 inhibition: the impact of substrate probe selection on in vitro inhibition profiles. Drug Metab Dispos. 2008 Mar;36(3):523-8. Epub 2007 Nov 29. [PubMed:18048485]
  2. Li XQ, Andersson TB, Ahlstrom M, Weidolf L: Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos. 2004 Aug;32(8):821-7. [PubMed:15258107]
  3. Li XQ, Weidolf L, Simonsson R, Andersson TB: Enantiomer/enantiomer interactions between the S- and R- isomers of omeprazole in human cytochrome P450 enzymes: major role of CYP2C19 and CYP3A4. J Pharmacol Exp Ther. 2005 Nov;315(2):777-87. Epub 2005 Aug 10. [PubMed:16093273]
  4. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  5. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  6. Yamazaki H, Inoue K, Shaw PM, Checovich WJ, Guengerich FP, Shimada T: Different contributions of cytochrome P450 2C19 and 3A4 in the oxidation of omeprazole by human liver microsomes: effects of contents of these two forms in individual human samples. J Pharmacol Exp Ther. 1997 Nov;283(2):434-42. [PubMed:9353355]
  7. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Details
2. Cytochrome P450 3A4
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
Inducer
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Li XQ, Weidolf L, Simonsson R, Andersson TB: Enantiomer/enantiomer interactions between the S- and R- isomers of omeprazole in human cytochrome P450 enzymes: major role of CYP2C19 and CYP3A4. J Pharmacol Exp Ther. 2005 Nov;315(2):777-87. Epub 2005 Aug 10. [PubMed:16093273]
  2. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  3. Botsch S, Gautier JC, Beaune P, Eichelbaum M, Kroemer HK: Identification and characterization of the cytochrome P450 enzymes involved in N-dealkylation of propafenone: molecular base for interaction potential and variable disposition of active metabolites. Mol Pharmacol. 1993 Jan;43(1):120-6. [PubMed:8423765]
  4. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  5. Turpeinen M, Uusitalo J, Jalonen J, Pelkonen O: Multiple P450 substrates in a single run: rapid and comprehensive in vitro interaction assay. Eur J Pharm Sci. 2005 Jan;24(1):123-32. [PubMed:15626586]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
Inducer
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Details
4. Cytochrome P450 2C9
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C18
Uniprot ID
P33260
Uniprot Name
Cytochrome P450 2C18
Molecular Weight
55710.075 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, nad(p)h as one donor, and incorporation of one atom of oxygen
Specific Function
Catalyzes the side-chain cleavage reaction of cholesterol to pregnenolone.
Gene Name
CYP11A1
Uniprot ID
P05108
Uniprot Name
Cholesterol side-chain cleavage enzyme, mitochondrial
Molecular Weight
60101.87 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Vitamin d 24-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A1
Uniprot ID
P04798
Uniprot Name
Cytochrome P450 1A1
Molecular Weight
58164.815 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1B1
Uniprot ID
Q16678
Uniprot Name
Cytochrome P450 1B1
Molecular Weight
60845.33 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Organic anion transmembrane transporter activity
Specific Function
May act as an inducible transporter in the biliary and intestinal excretion of organic anions. Acts as an alternative route for the export of bile acids and glucuronides from cholestatic hepatocyte...
Gene Name
ABCC3
Uniprot ID
O15438
Uniprot Name
Canalicular multispecific organic anion transporter 2
Molecular Weight
169341.14 Da
References
  1. Hitzl M, Klein K, Zanger UM, Fritz P, Nussler AK, Neuhaus P, Fromm MF: Influence of omeprazole on multidrug resistance protein 3 expression in human liver. J Pharmacol Exp Ther. 2003 Feb;304(2):524-30. [PubMed:12538803]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Pauli-Magnus C, Rekersbrink S, Klotz U, Fromm MF: Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein. Naunyn Schmiedebergs Arch Pharmacol. 2001 Dec;364(6):551-7. [PubMed:11770010]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both fro...
Gene Name
ABCG2
Uniprot ID
Q9UNQ0
Uniprot Name
ATP-binding cassette sub-family G member 2
Molecular Weight
72313.47 Da
References
  1. Breedveld P, Zelcer N, Pluim D, Sonmezer O, Tibben MM, Beijnen JH, Schinkel AH, van Tellingen O, Borst P, Schellens JH: Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions. Cancer Res. 2004 Aug 15;64(16):5804-11. [PubMed:15313923]
  2. Suzuki K, Doki K, Homma M, Tamaki H, Hori S, Ohtani H, Sawada Y, Kohda Y: Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy. Br J Clin Pharmacol. 2009 Jan;67(1):44-9. doi: 10.1111/j.1365-2125.2008.03303.x. Epub 2008 Nov 17. [PubMed:19076159]

Drug created on June 13, 2005 07:24 / Updated on December 10, 2017 17:18